Answers are grounded in this paper and cite their sources.
In patients with DCIS, COX-2 may predict recurrence, aiding clinical decision making. A combination of an aromatase inhibitor and celecoxib has significant biological effect and may be integrated into treatment of COX2-positive DCIS at high risk of recurrence.
No takes yet. Share an insight, caveat, or question.
Generali et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: